1-3 of 3
Bea Tanis, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Claudia A.M. Stege, MD, Bronno van der Holt, Ulf-Henrik Mellqvist, MD, Mark-David Levin, PhD, Morten Salomo, Niels Abildgaard, MD, Gerard Bos, MDPhD, Heleen Visser-Wisselaar, Markus Hansson, MD PhD, Annette van der Velden, MD, Wendy Deenik, MD, Astrid Gruber, MD PhD, Jules L.L.M. Coenen, MD, Torben Plesner, MD, Saskia Klein, MD, Bea Tanis, MD PhD, Damian L. Szatkowski, MDPhDMSc, Rolf Brouwer, MD PhD, Matthijs Westerman, MD, Maria Berhardina Leijs, MD, Harm Sinnige, Einar Haukaas, Klaas van der Hem, MD PhD, Marc Durian, MD, Vera Mattijssen, MD PhD, Peter Gimsing, DO, PhD, Niels WCJ Van De Donk, Marian Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3146.
https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146
Published: 2017
Journal Articles

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Saskia K. Klein, MD PhD, Esther G.M. De Waal, MD, Corien M. Eeltink, RN, MA, ANP, Paula F. Ypma, MD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD PhD, Bea Tanis, MD PhD, Monique S. Slee-Valentijn, MD, Monique Minnema, Heleen Visser-Wisselaar, PhD, Claudia Stege, MD, Niels W.C.J. van de Donk, MD PhD, Kazem Nasserinejad, MA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3305.
https://doi.org/10.1182/blood.V128.22.3305.3305
Published: 2016
Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Arjan A. van de Loosdrecht, MD PhD, Dana A Chitu, PhD, Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Heleen Visser-Wisselaar, PhD, Annelies Verbrugge, Petra Muus, MD PhD, Inge de Greef, MD PhD, Pierre W Wijermans, MD, Joop H. Jansen, PhD, Saskia K. Klein, MD PhD, Edo Vellenga, MD PhD, Marie-Cecile Legdeur, MD PhD, Wendy Deenik, MD PhD, Mojca jongen-Lavrencic, MD PhD, Rien van Marwijk-Kooy, Bea Tanis, MD PhD, Jurgen Wegman, Tanja van Maanen, Gert Ossenkoppele, MD PhD
Journal: Blood
Blood (2016) 128 (22): 224.
https://doi.org/10.1182/blood.V128.22.224.224
Published: 2016